SR One Capital Management LP Buys Shares of 443,661 KALA BIO, Inc. (NASDAQ:KALA)

SR One Capital Management LP bought a new stake in KALA BIO, Inc. (NASDAQ:KALA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th largest position. SR One Capital Management LP owned about 15.76% of KALA BIO at the end of the most recent quarter.

Wall Street Analyst Weigh In

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price target on shares of KALA BIO in a report on Monday, August 19th.

KALA BIO Stock Performance

KALA BIO stock opened at $5.79 on Friday. The business has a 50 day moving average of $6.25 and a 200-day moving average of $6.66. The company has a market capitalization of $16.30 million, a P/E ratio of -0.38 and a beta of -2.12. KALA BIO, Inc. has a 1 year low of $4.21 and a 1 year high of $10.97. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.07 and a quick ratio of 3.07.

KALA BIO (NASDAQ:KALA) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($3.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.40) by $1.24. On average, equities research analysts predict that KALA BIO, Inc. will post -11.76 earnings per share for the current year.

Insider Activity

In other news, CEO Mark T. Iwicki sold 15,168 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $4.75, for a total value of $72,048.00. Following the transaction, the chief executive officer now owns 263,755 shares in the company, valued at approximately $1,252,836.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 23,984 shares of company stock valued at $113,924. Company insiders own 13.40% of the company’s stock.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.